心脉医疗收盘上涨1.55%，滚动市盈率33.06倍，总市值147.91亿元

Core Viewpoint - The company, Xinmai Medical, has seen a decline in its stock performance, with a current PE ratio of 33.06, significantly lower than the industry average of 57.51, indicating potential undervaluation in the medical device sector [1][3]. Company Overview - Xinmai Medical specializes in the research, production, and sales of interventional medical devices for aortic and peripheral blood vessels, with key products including stent systems and balloon catheters [2]. - The company has received several accolades, including the Shanghai Government Quality Gold Award and recognition as one of the top 30 value companies on the Sci-Tech Innovation Board [2]. Financial Performance - In the first quarter of 2025, Xinmai Medical reported a revenue of 332 million yuan, representing a year-on-year decrease of 7.23%, while net profit fell by 29.66% to 130 million yuan, with a gross margin of 69.61% [2]. Shareholder Information - As of March 31, 2025, Xinmai Medical had 18,176 shareholders, an increase of 523 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Industry Comparison - Xinmai Medical's PE ratio of 33.06 places it 64th in the medical device industry, which has an average PE of 57.51 and a median of 41.25, indicating that the company is trading below the industry norms [1][3].